17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
03:01 , May 6, 2017 |  BioCentury  |  Product Development

Finding gems in India

For Agios Pharmaceuticals Inc. , the decision to license molecules from Indian CRO Aurigene Discovery Technologies Ltd. was a special case intended to save time getting a new project off the ground, rather than part...
20:16 , Mar 24, 2017 |  BC Week In Review  |  Company News

Agios Pharmaceuticals, Celgene deal

Celgene will pay Agios $8 million after designating a development candidate to treat methylthioadenosine phosphorylase (MTAP)-deleted cancers under a 2010 deal. Celgene has an option to co-develop and co-commercialize the program which it can exercise...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Agios, Celgene deal

The companies amended their 2010 deal and returned worldwide rights to AG-120 to Agios. The inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) is in Phase I testing to treat acute myelogenous leukemia (AML), solid tumors...
00:31 , May 18, 2016 |  BC Extra  |  Top Story

Celgene, Agios form new oncology deal, revise another

Celgene Corp. (NASDAQ:CELG) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO) formed a new research collaboration to explore metabolic immuno-oncology. The companies also amended their 2010 cancer metabolism deal, returning to Agios worldwide rights to mutated isocitrate dehydrogenase...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methionine adenosyltransferase 2A (MAT2A); protein arginine methyltransferase 5 (PRMT5); RIO kinase 1 (RIOK1); methylthioadenosine phosphorylase (

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting the MAT2A / PRMT5 / RIOK1 axis could help treat MTAP-deficient colon cancer. In a human MTAP-deficient colon cancer cell line, shRNA targeting MAT2A,...
08:00 , Mar 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Various Coronary artery disease (CAD); type 2 diabetes Cyclin dependent kinase inhibitor 2B (CDKN2B; INK4B; MTS2); interferon-a21 (IFNA21); methylthioadenosine phosphorylase (MTAP)...
08:00 , Feb 24, 2011 |  BC Innovations  |  Targets & Mechanisms

Inflaming cardiovascular passions

Ever since a 2007 genomewide association study uncovered a region of chromosome 9 as a major player in determining risk for cardiovascular diseases, researchers have struggled to understand how locus 9p21 actually causes disease. Now,...